NACL Industries revises MD remuneration at 39th AGM

1 min read     Updated on 22 Jul 2026, 09:31 PM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

NACL Industries Limited's 39th AGM on July 22, 2026, saw the approval of financial statements for FY26 and a revision in the MD's remuneration. The meeting also addressed qualifications in the Secretarial Auditors' Report and ratified cost auditor payments.

powered bylight_fuzz_icon
46281682

*this image is generated using AI for illustrative purposes only.

NACL Industries Limited held its 39th Annual General Meeting on July 22, 2026, approving the audited financial statements for the year ended March 31, 2026, and revising the remuneration of its Managing Director & Chief Executive Officer. The meeting, convened via video conferencing, was presided over by Chairman Mr. Arun Alagappan and included the re-appointment of a director and the ratification of cost auditor fees.

The Board confirmed that the Statutory Auditors' Report contained no qualifications, observations, or comments adversely affecting the company's operations. However, qualifications in the Secretarial Auditors' Report were addressed, with the Board providing appropriate explanations in its report. The Chairman highlighted the company's strategic focus on "Stabilize" and "Build" to navigate industry volatility and drive operational recovery.

Resolutions Passed

Shareholders voted on five items of business, including four ordinary resolutions and one special resolution. The remote e-voting facility was available from July 19 to July 21, 2026, with Mr. R. Sridharan of R. Sridharan & Associates appointed as the Scrutinizer.

Resolution Type Description
Ordinary Adoption of Audited Standalone Financial Statements for FY26
Ordinary Adoption of Audited Consolidated Financial Statements for FY26
Ordinary Re-appointment of Mr. Sankarasubramanian S, Non-Executive Director
Ordinary Ratification of Cost Auditor remuneration for FY27
Special Revision of remuneration for Dr. Raghuram Devarakonda, MD & CEO

Key Attendees and Governance

The meeting was attended by key personnel, including Dr. Raghuram Devarakonda, Managing Director & CEO, Mr. N. Shankar, Chief Financial Officer, and Mr. Rajesh Mukhija, Company Secretary. Several independent directors joined via video conferencing from Chennai. Representatives from M/s. S.R. Batliboi & Associates LLP (Statutory Auditors), M/s. Sridharan & Associates (Secretarial Auditors), and M/s. Narasimha Murthy & Co (Cost Auditors) were also present.

The Chairman noted that the Register of Directors, Key Managerial Personnel shareholding, and Register of Contracts were available for inspection. Additionally, the Secretarial Auditor's certificate confirming compliance with SEBI regulations regarding Employee Stock Option Schemes was made accessible to members.

Historical Stock Returns for NACL Industries

1 Day5 Days1 Month6 Months1 Year5 Years
-3.14%-4.98%-5.07%+23.89%-29.12%+185.64%

How will the revised remuneration package for the MD & CEO align with the company's 'Stabilize' and 'Build' strategy?

What specific operational recovery measures does NACL Industries plan to implement to navigate industry volatility?

What were the qualifications in the Secretarial Auditors' Report, and how will their resolution impact future compliance?

NACL Industries Q1 profit rises 65%; EBITDA margin expands to 10.8%

2 min read     Updated on 22 Jul 2026, 02:05 PM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

NACL Industries reported a 64.8% rise in standalone Q1 net profit to ₹23.57 crore, with EBITDA improving to ₹414 million from ₹381 million YoY and EBITDA margin expanding to 10.8% from 8.51%. Consolidated net profit rose to ₹20.84 crore from ₹13.04 crore. The Board also approved the divestment of its entire stake in associate company Nasense Labs Private Limited for ₹8,15,29,967.

powered bylight_fuzz_icon
46254794

*this image is generated using AI for illustrative purposes only.

NACL Industries Limited reported a standalone net profit of ₹23.57 crore for the quarter ended June 30, 2026, marking a 64.8% increase from ₹14.30 crore in the corresponding period of the previous year. Revenue from operations for Q1FY27 stood at ₹382.25 crore, while total income was ₹384.26 crore. The Board of Directors approved the unaudited financial results on July 22, 2026.

Financial Performance

The company's EBITDA for the quarter stood at ₹414 million, up from ₹381 million in the same period last year, reflecting improved operational efficiency. EBITDA margin expanded meaningfully to 10.8% from 8.51% on a year-on-year basis. On a consolidated basis, net profit rose to ₹20.84 crore from ₹13.04 crore in Q1FY26, while consolidated revenue from operations was ₹383.33 crore compared to ₹448.36 crore in the prior year period. The basic and diluted earnings per share (EPS) for the standalone entity were recorded at ₹1.01 for the quarter, up from ₹0.66 in the same period last year.

The table below summarises the key financial metrics for the quarter:

Metric Standalone Q1FY27 (₹ in Lakhs) Standalone Q1FY26 (₹ in Lakhs) Consolidated Q1FY27 (₹ in Lakhs) Consolidated Q1FY26 (₹ in Lakhs)
Revenue from Operations 38,225 43,850 38,333 44,836
Total Income 38,426 44,077 38,522 44,953
Net Profit 2,357 1,430 2,084 1,304
Basic EPS (₹) 1.01 0.66 0.89 0.60
EBITDA Metric Q1FY27 Q1FY26
EBITDA ₹414 million ₹381 million
EBITDA Margin 10.80% 8.51%

Strategic Divestment

The Board approved the proposal to divest the company's entire equity stake in Nasense Labs Private Limited, an associate company. The stake will be sold to Mr. Kanumuru Satyanarayana Raju for a total consideration of ₹8,15,29,967. The transaction is expected to be completed within the next three months, subject to the fulfilment of terms and conditions outlined in the Share Purchase Agreement. Post-completion, Nasense Labs Private Limited will cease to be an associate company of NACL Industries Limited.

Operational Details

The unaudited financial results were reviewed by M/s. S R Batliboi & Associates, Statutory Auditors of the company, who issued an unmodified conclusion. The company also reported that funds raised through a rights issue in December 2025 have been utilised for the intended purposes, with an unutilised amount of ₹2,445 lakhs deposited in an earmarked bank account. Additionally, the company allotted 65,000 equity shares during the quarter pursuant to the exercise of stock options.

Historical Stock Returns for NACL Industries

1 Day5 Days1 Month6 Months1 Year5 Years
-3.14%-4.98%-5.07%+23.89%-29.12%+185.64%

How does NACL Industries plan to utilize the proceeds from the divestment of Nasense Labs?

Can the expansion in EBITDA margins be sustained throughout the remainder of FY27 given the decline in consolidated revenue?

What specific capital expenditure or growth initiatives are planned for the remaining unutilized rights issue funds of ₹2,445 lakhs?

More News on NACL Industries

1 Year Returns:-29.12%